Cytokinetics, Incorporated (CYTK) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Analysis Summary
Cytokinetics, Incorporated reported revenue of $88.0M in the most recent fiscal year, growing at a 5-year CAGR of 9.5%.
Trailing-twelve-month margins: gross margin 85.0%, operating margin -9.9%, net margin -12.6%.
At the current price of $73.45, CYTK has negative trailing earnings (P/E not meaningful) and an ROE of 119.00%. Market capitalisation stands at $9.1B.
Balance sheet quality for CYTK: current ratio of 4.5, net debt of $402.0M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $73.45 |
| Market Cap | $9.1B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -52.77 |
| EV / EBITDA | -11.34 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 119.00% |
| Return on Invested Capital | -47.74% |
| Return on Assets | -55.10% |
| Gross Margin | 84.97% |
| Operating Margin | -992.98% |
| Net Margin | -1259.87% |
Financial Health
| Debt / Equity | -7.32 |
| Current Ratio | 6.66 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -1.99 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CYTK | Cytokinetics, Incorporated | $9.1B | 119.0% | ||
| JAZZ | Jazz Pharmaceuticals plc | $15.5B | 15.84 | 3.17 | 21.4% |
| AXSM | Axsome Therapeutics, Inc. | $10.9B | |||
| ABVX | Abivax S.A. | $7.5B | 15.11 | -73.9% | |
| HALO | Halozyme Therapeutics, Inc. | $12.7B | 30.18 | 86.81 | |
| CRSP | CRISPR Therapeutics AG | $5.0B | 2.86 | ||
| CORT | Corcept Therapeutics Incorporated | $12.1B | 207.35 | 16.10 | 8.4% |
Price Performance
| 1 month | -8.82% |
| 3 months | -11.92% |
| Year-to-date | +9.21% |
| 1 year | +45.90% |
| 3 years | +104.87% |
52-Week Range
| 52-week High | $88.31 |
| 52-week Low | $47.22 |
| Avg Volume (90d) | 2.1M |
Related companies: ABVX · AXSM · CORT · CRSP · HALO · JAZZ · MRUS
Explore sector: Healthcare · Biotechnology
More sections of CYTK: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks